77862-95-4

Usage

Uses

Used in Pharmaceutical Research:
1H-Imidazo[4,5-b]pyridine-6-carboxylic acid, methyl ester is used as a building block for the development of new pharmaceutical compounds due to its unique heterocyclic structure and potential biological activities. It aids in the creation of novel drug candidates that may have therapeutic applications in various medical fields.
Used in Organic Synthesis:
In the field of organic synthesis, 1H-Imidazo[4,5-b]pyridine-6-carboxylic acid, methyl ester serves as a key intermediate for the synthesis of a variety of complex organic molecules. Its reactivity and structural features make it a valuable component in the production of specialty chemicals and advanced materials.
Used as a Reagent in Chemical Reactions:
1H-Imidazo[4,5-b]pyridine-6-carboxylic acid, methyl ester is utilized as a reagent in various chemical reactions, facilitating the production of a range of other compounds. Its versatility in chemical processes underscores its importance in the synthesis of diverse chemical entities for research and industrial applications.

Upstream product

• 38875-53-5 5-bromo-pyridine-2,3-diamine 
• 67-56-1 methanol 
• 201230-82-2 carbon monoxide 
• 28279-49-4 6-bromo-3H-imidazo[4,5-b]pyridine 
• 104685-75-8 methyl 2-amino-3-nitropyridine-5-carboxylate 
• 64-18-6 formic acid 
• 104685-76-9 5,6-diamino-nicotinic acid methyl ester 
• 122-51-0 orthoformic acid triethyl ester 

Relevant academic research and scientific papers

Convenient synthesis of imidazo[1,5-a]pyrimidine derivatives and their unusual recyclization into 3H-imidazo[4,5-b]pyridine derivatives

[Figure not available: see fulltext.] New derivatives of imidazo[1,5-a]pyrimidine have been synthesized by cyclization of in situ generated 1H-imidazol-4(5)-amine with 1,3-diketones or malondialdehyde derivatives. Utilization of asymmetrical 1,3-diketones leads to the formation of a mixture of regioisomers. The discovered conversion of imidazo[1,5-a]pyrimidine core into 3H-imidazo[4,5-b]pyridine that takes place only under acidic conditions can be considered as a new version of Dimroth rearrangement involving cleavage of C–N bond and formation of C–C bond.

HETEROCYCLIC COMPOUNDS AND USE THEREOF AS MODULATORS OF TYPE III RECEPTOR TYROSINE KINASES

Provided herein are heterocyclic compounds for treatment of CSF1R, FLT3, KIT, and/or PDGFRβ kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.

Thrombin inhibitors

Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: or a pharmaceutically acceptable salt thereof, wherein b is NY or O; c is CY2or N; d is CY3or N; e is CY4or N; f is CY5or N; g is CY6or N; Y4, Y5, and Y6are independently hydrogen, C1-4alkyl, or halogen; Y1and Y2are independently hydrogen, C1-4alkyl, C3-7cycloalkyl, halogen, NH2, OH or C1-4alkoxy, and Y3is hydrogen, C1-4alkyl, C3-7cycloalkyl, halogen, —CN, NH2, OH or C1-4alkoxy; A is and W, W1, R1, R3, R4, R5, X and Z are defined in the specification.

Thrombin inhibitors

Compounds of the invention are useful in inhibiting thrombin and treating blood coagulation and cardiovascular disorders and have the following structure: wherein R3 is hydrogen or halogen, and u is N or CH.